ArticleJournal of immunology (Baltimore, Md. : 1950)2011
CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.Theranostics · 2021Pooled it
- Entry Without Expression: Internalisation Does Not Predict mRNA Translation for Targeted Lipid Nanoparticles.Small science · 2026Article
- Novel PE-DT-fusion toxin enhances internalization and target-dependently restores the cytotoxicity of recombinant immunotoxins.Frontiers in pharmacology · 2026Article
- Molecular Insights into the Engagement of High-Affinity Sialylated Ligands to Human CD22.JACS Au · 2025Article
- A Method for High-Throughput Screening of Monoclonal Antibody Internalization Using a DNA/Protein Molecular Staple.Small methods · 2025Article
- A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles.Nature nanotechnology · 2025Article
- M2-Like Macrophages Exhibit Sialic Acid-Enhanced Efferocytosis via the Siglec CD22.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses.Science advances · 2025Article
- Rational design of FVIII sialylated peptides to target Siglec-3 and Siglec-9 and improve peptide formulations for reverse vaccines.Frontiers in bioengineering and biotechnology · 2025Article
- Sialic acid in the regulation of blood cell production, differentiation and turnover.Immunology · 2024Review
- Immune-related adverse events of antibody-based biological medicines in cancer therapy.Journal of cellular and molecular medicine · 2024Review
- Quantitative Measurement of Plasma Membrane Protein Internalisation and Recycling in Heterogenous Cellular Samples by Flow Cytometry.Bio-protocol · 2024Article
- Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.Science and technology of advanced materials · 2024Article
- Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.Seminars in immunology · 2023Review
- The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.EMBO reports · 2023Article
- Review
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- Reduced cytotoxicity by mutation of lysine 590 ofImmunotherapy advances · 2022Article
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
CD22 is a member of the sialic acid-binding Ig-like lectin (Siglec) family that is known to be a regulator of B cell signaling. Its B cell-specific expression makes it an attractive target for immunotoxin-mediated B cell depletion therapy for the treatment of B cell lymphomas and autoimmune diseases. Although CD22 is well documented to be an endocytic receptor, it is believed that after internalization, it is targeted for degradation. We show in this study that CD22 is instead constitutively recycled to the cell surface. We also find that glycan ligand-based cargo is released from CD22 and accumulates intracellularly as CD22 recycles between the cell surface and endosomal compartments. In contrast, Abs to CD22 do not accumulate but remain bound to CD22 and recycle to the cell surface. The results have implications for development of agents that target CD22 as an endocytic receptor for delivery of cytotoxic cargo to B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.